Concepedia

Kristen Lantz

KL

Statistics

Publications

15

Citations

1.1K

H-Index

14

Active since

2003

Affiliations

Janssen (United States)(Current)

University of Calgary

Instituto de Investigación Biomédica de Salamanca

Institute of Cancer Research

Emory University

Kristen Lantz is an author at Janssen (United States) specializing in cancer immunotherapy, relapsed multiple myeloma, and pharmacology.

Publications per year

2003–2025

15

Publications

15

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

María‐Victoria Mateos, Hareth Nahi, Wojciech Legieć et al. · The Lancet Haematology · 2020 · 241 citations · Full text

, , +14

Inhibition of PTP1B by Trodusquemine (MSI‐1436) Causes Fat‐specific Weight Loss in Diet‐induced Obese Mice

Kristen Lantz, Susan Hart, Sonia Lobo Planey et al. · Obesity · 2010 · 229 citations · Full text

, , +17

Foxa2 regulates multiple pathways of insulin secretion

Kristen Lantz, Marko Z. Vatamaniuk, John Brestelli et al. · Journal of Clinical Investigation · 2004 · 164 citations · Full text

, , +15

Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment

Pamela L. Clemens, Xiaoyu Yan, Henk M. Lokhorst et al. · Clinical Pharmacokinetics · 2016 · 83 citations · Full text

, , +17

<i>Foxa1</i>-Deficient Mice Exhibit Impaired Insulin Secretion due to Uncoupled Oxidative Phosphorylation

Marko Z. Vatamaniuk, Rana K. Gupta, Kristen Lantz et al. · Diabetes · 2006 · 60 citations · Full text

, , +17

1–5 of 15